Related Experiment Videos
Novel targeted therapies in ovarian and uterine carcinosarcomas
Chanhee Han1, Gary Altwerger1, Gulden Menderes1
1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Abstract:
Carcinosarcomas (CSs) of the uterus and ovary are rare biologically aggressive tumors with poor prognosis. The development of novel, effective treatment strategies against CSs of the female genital tract remains an unmet medical need. Whole-exome sequencing studies have recently demonstrated mutations or aberrant activation of multiple genes/pathways in CSs including HER2, PI3K/AKT/mTOR, EGFR, MAPK, genes related to histones and chromatin structure, and genes related to cell-cycle regulation. The carcinomatous component of these biphasic tumors is suggested to be the catalyst in CS tumorigenesis. This article reviews the genetic landscapes and explores novel targeted treatment modalities against this deadly gynecologic tumor.
Insights
Uterine and ovarian carcinosarcomas (CSs) are aggressive cancers needing new treatments. Genetic studies reveal key mutations in pathways like HER2 and PI3K/AKT/mTOR, offering targets for novel therapies.
Area of Science:
- Gynecologic Oncology
- Cancer Genomics
- Molecular Pathology
Background:
- Carcinosarcomas (CSs) of the uterus and ovary are rare, aggressive tumors with poor prognoses.
- Effective treatment strategies for these female genital tract tumors are urgently needed.
- Recent whole-exome sequencing has identified numerous genetic alterations in CSs.
Purpose of the Study:
- To review the genetic landscape of uterine and ovarian carcinosarcomas.
- To explore novel targeted treatment modalities for these rare cancers.
Main Methods:
- Review of whole-exome sequencing studies.
- Analysis of identified mutations and aberrant gene/pathway activations.
- Exploration of targeted therapy implications.
Main Results:
- CSs exhibit mutations/aberrant activation in multiple genes/pathways, including HER2, PI3K/AKT/mTOR, EGFR, and MAPK.
- Genes involved in histone and chromatin structure, and cell-cycle regulation are also implicated.
- The carcinomatous component is hypothesized to drive CS tumorigenesis.
Conclusions:
- Understanding the genetic landscape of CSs is crucial for developing targeted therapies.
- Targeted treatment modalities show promise for improving outcomes in patients with these deadly gynecologic tumors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers
Inhibition of Cdk Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...